Biogen (BIIB) Q2 2026 earnings review
Topline Pivot Succeeds, But Margins Collapse Under Deal Weight
Biogen has officially crossed its strategic inflection point: its Growth Portfolio ($1.06B) has outpaced its legacy Multiple Sclerosis franchise ($963M), returning the company to topline growth. Total Q2 revenue accelerated to 3% YoY growth ($2.74B). However, the cost of this transformation is severe margin compression. Non-GAAP EPS plunged 34% YoY to $3.60, crushed by Apellis acquisition dilution, increased operational spend, and massive IPR&D charges. While management raised underlying guidance, the reported FY26 EPS outlook was slashed to $12.00-$13.00. The bottom line is bleeding to fund the topline pivot.
🐂 Bull Case
The Growth Portfolio surged 24% YoY, fully offsetting the legacy MS drag. Newly acquired assets SYFOVRE ($162M) and EMPAVELI ($46M) add immediate commercial scale to a newly formed Specialized Immunology segment.
Management upgraded FY26 revenue guidance to a mid-single digit percentage increase (up from roughly flat/low-single), proving confidence in the commercial execution of recent launches.
🐻 Bear Case
The Apellis acquisition will dilute FY26 Non-GAAP EPS by ~$0.85, compounded by ~$3.00 in IPR&D charges. The pivot from a mature, high-margin MS business to early-launch products is destroying near-term profitability.
The MS portfolio is not just declining; the bleed is accelerating. Revenues fell 13% YoY to $963M, with TYSABRI and TECFIDERA facing intensifying generic and biosimilar competition.
⚖️ Verdict: ⚪
Neutral. Biogen has successfully engineered a return to topline growth, which is exactly what the market demanded. However, the sheer magnitude of the margin deterioration and integration costs from the Apellis deal make this a 'show-me' story on earnings recovery.
Key Themes
Apellis Deal Instantly Mints a New Franchise
The completed Apellis acquisition immediately established a $128M 'Specialized Immunology' segment for Biogen in Q2. SYFOVRE posted its strongest quarterly demand yet ($162M total, $97M recognized by Biogen post-close). This gives Biogen a critical nephrology and ophthalmology commercial footprint to support the future felzartamab launch.
Cost Base Inflation Reversing Prior Efficiency Gains
Biogen's 'Fit for Growth' cost-cutting narrative is reversing. Non-GAAP SG&A ballooned 17% YoY to $680M, and Non-GAAP R&D spiked 24% to $490M. This was driven by the integration of Apellis headcount and increased clinical trial spend. The company must now prove it can wring $250M in promised run-rate synergies from Apellis by 2027.
Rare Disease Portfolio Firing on All Cylinders
Rare disease revenues are accelerating, up 11% YoY to $602M. SKYCLARYS surged 29% YoY to $168M, driven by European expansion. ZURZUVAE leapt 53% YoY to $71M and launched in Germany. Crucially, SPINRAZA stabilized with 2% growth ($402M), benefiting from the high-dose regimen conversion exceeding internal expectations.
VUMERITY Inventory Dynamics Masking Weakness
While management praises the resilience of the U.S. MS portfolio, VUMERITY—the intended long-term oral MS anchor—decelerated, with revenue falling 7% YoY to $197M. Management blamed 'inventory dynamics,' but given the broader 13% collapse in the MS segment, this requires close monitoring.
LEQEMBI IQLIK Subcutaneous Approval
LEQEMBI in-market sales reached $184M (+15% YoY). More importantly, the FDA approved LEQEMBI IQLIK for at-home initiation. This technological innovation removes the massive infusion center bottleneck that has plagued the launch since day one, paving the way for faster adoption and higher patient retention.
Data Readout Supercycle Begins
Biogen is entering a dense catalyst period. Registrational data for litifilimab in SLE is due by end of 2026. Data for felzartamab (AMR), litifilimab (CLE), and zorevunersen (Dravet) are slated for next year. Additionally, diranersen demonstrated proof-of-concept as the first tau-directed agent to reduce tau pathology in AD, officially moving into Phase 3.
Macro FX Headwinds Constraining Real Growth
Currency fluctuations continue to mask underlying performance. While reported total revenue grew 3.4% YoY, constant currency growth was only 1.6%. In the critical MS segment, constant currency decline was 14.4%, worse than the 13.0% reported decline, illustrating that the global generic erosion is actually more severe than headline numbers suggest.
Other KPIs
Stable. Up dramatically from $134M in Q2 2025 (which was artificially depressed by a $745M cash tax payment). However, total debt has ballooned to $8.1B to finance the Apellis transaction, leaving net debt at $6.8B. FCF generation will need to remain robust to de-lever the balance sheet by the end of 2027 as promised.
Accelerating significantly from $47M a year ago. This line item continues to hammer GAAP and Non-GAAP profitability, reflecting Biogen's aggressive external BD strategy (including a $15M payment to Ionis for BIIB147).
Guidance
Accelerating. Upgraded from previous guidance of 'flat to increasing 1%'. Reflects the addition of Apellis revenues and continued strong traction in the Growth Portfolio.
Reversing downward. Management increased the 'Underlying' business expectation by $0.60, but the actual reported guidance was slashed violently from the prior $14.25-$15.25. The cut incorporates ~$2.00 in IPR&D charges and ~$0.85 in Apellis dilution. This explicitly contradicts the purely optimistic narrative of a stronger business outlook.
Accelerating. This implies an average of ~$1.34B per quarter in OpEx for the back half of the year, higher than the $1.17B reported in Q2. It confirms that the elevated cost structure inherited from Apellis and pipeline investments is here to stay.
Key Questions
Apellis Synergy Execution
You are guiding to $250M in run-rate synergies from the Apellis deal exiting 2027. Given the sharp spike in SG&A this quarter, where exactly will these cuts come from without stalling SYFOVRE's commercial momentum?
VUMERITY Weakness
VUMERITY revenue declined 7% YoY, which was attributed to inventory dynamics. Excluding inventory, what is the underlying volume demand growth, and is it facing any secondary pressure from broader MS genericization?
LEQEMBI IQLIK Ramp
With the approval of LEQEMBI IQLIK for at-home initiation, how quickly do you expect the current bottleneck at infusion centers to clear, and how is this factored into your second-half revenue projections?
Debt De-leveraging Pathway
Net debt now sits at $6.8B following the Apellis acquisition. Given the heavy near-term EPS dilution, what is your precise timeline and FCF allocation strategy for paying down the $2B in transaction financing?